Pharmacokinetics of Lithium in Patients treated with Controlled Release Lithium Formulations

Phillips, Jonathan D.; Myers, DJ; King, Justin R.; Armond, A. D.; Derham, C; Puranik, Amey S.; Corbett, John A.; Birch, Nicholas J.

doi:10.1097/00004850-199001000-00007

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacokinetic studies have shown that very slow release lithium formulations have poor bioavailability. 92,330,331 Studies of a range of formulations [332][333][334] show that the time course of lithium concentration in blood plasma has a characteristic short absorptive phase with a sharp peak between 1 and 4 h after the oral dose. The time of the peak is variable between subjects, but each individual is relatively internally consistent.…”

Section: Pharmacokinetics Of Lithiummentioning

confidence: 99%

“…Certain preparations are marketed as “controlled release” formulations of lithium carbonate, yet the precise meaning of the term “controlled release” has been subject to misunderstanding and has occasionally been taken to mean “slow release”. Pharmacokinetic studies have shown that very slow release lithium formulations have poor bioavailability. ,, Studies of a range of formulations − show that the time course of lithium concentration in blood plasma has a characteristic short absorptive phase with a sharp peak between 1 and 4 h after the oral dose. The time of the peak is variable between subjects, but each individual is relatively internally consistent.…”

Section: Pharmacokinetics Of Lithiummentioning

confidence: 99%

See 1 more Smart Citation

Inorganic Pharmacology of Lithium

Birch¹

1999

Chem. Rev.

View full text Add to dashboard Cite

Section: Pharmacokinetics Of Lithiummentioning

confidence: 99%

Section: Pharmacokinetics Of Lithiummentioning

confidence: 99%

Inorganic Pharmacology of Lithium

Birch¹

1999

Chem. Rev.

View full text Add to dashboard Cite

Lithium

Müller‐Oerlinghausen¹,

Kaschka²,

Schöpf³

1993

Neuro-Psychopharmaka

View full text Add to dashboard Cite

Lithium

Müller‐Oerlinghausen¹,

Kaschka²

2002

Neuro-Psychopharmaka Ein Therapie-Handbuch

View full text Add to dashboard Cite

Lithium 12.1 Pharmakologie 12.1.1 Pharmakokinetik B. MiUler-Oerlinghausen Die medizinische Anwendung von Lithiumsalzen wird durch die geringe therapeutische Breite des Lithiumions erschwert. Ahnlich wie bei der Therapie mit z. B. Herzglykosiden oder Theophyllin, wo die optimale Dosierung ebenfalls anhand des Serumspiegels uberpruft wird, sind deshalb einige Kenmnisse der Pharmakokinetik notwendig, um einen Lithiumserumspiegel richtig zu interpretieren und um in der jeweiligen therapeutischen Situation (z. B. erste Einstellung auf Lithium, Kontrolle der laufenden Therapie, Oherprufung der Patientencompliance, Diagnose einer Intoxikation oder Dosiskorrektur nach Beginn einer relevanten Zusatzmedikation) die richtigen KontrollmaBnahmen im richtigen Zeitintervall auszuwahlen. Dazu gehart ein Grundverstanclnis cler Resorptionsbedingungen, insbesondere bei Anwenclung verschiedener galenischer Praparationen, cler Velteilung und vor allem der Elimination des Lithiumions. Auch eine Kenmnis cler moglichen pharmakokinetischen Interaktionen durch gleichzeitig ge-Neuro-Psvchopharmaka, 3d. 3, 2. AUfl. Riederer P. / Laux G. / P6ldinger W. (Hrsg.

show abstract

Pharmacokinetics of Lithium in Patients treated with Controlled Release Lithium Formulations

Cited by 6 publications

References 0 publications

Inorganic Pharmacology of Lithium

Inorganic Pharmacology of Lithium

Lithium

Lithium

Contact Info

Product

Resources

About